Eldec Pharmaceuticals is focused on developing novel peptide therapeutics aimed at treating chronic lung diseases. The company has identified naturally-occurring peptides in the lung that play a crucial role in inhibiting inflammation, tissue remodeling, and fibrosis. These peptides are being optimized to enhance their potency, making them more effective as drug candidates. One of the key innovations from Eldec is ELD607, a first-in-class modulator of Orai1, which is a significant regulator of inflammation and tissue remodeling processes. In preclinical studies, ELD607 has demonstrated the ability to reverse existing lung damage in various animal models, showcasing its potential as a transformative therapy for patients suffering from chronic lung conditions.

The founders of Eldec Pharmaceuticals are recognized pioneers in the field of lung biology, particularly in their work on Orai1 and its inhibitors. Their commitment to advancing new therapies is evident in their approach to tackling diseases that have seen limited success with existing treatments. By leveraging their expertise in lung biology and focusing on the therapeutic potential of naturally occurring peptides, Eldec aims to provide innovative solutions for patients in need, emphasizing their dedication to improving health outcomes in chronic lung disease management.

United States

Eldec Pharmaceuticals Inc. is a preclinical biotech company focused on developing novel peptide therapeutics to treat inflammatory and autoimmune diseases. The company was spun out of the University of North Carolina at Chapel Hill (UNC-CH) in 2017 and is currently developing peptide-based therapies to treat lung infections and lung inflammation.

Eldec Pharmaceuticals

Company Details